Oncotelic Therapeutics, Inc. (OTLC)
USD 0.05
(-25.71%)
USD 0.05
(-25.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.64 Million USD | 94.19% |
| 2022 | -9.72 Million USD | -6.53% |
| 2021 | -9.12 Million USD | -20.32% |
| 2020 | -7.58 Million USD | -75.94% |
| 2019 | -4.31 Million USD | -43.6% |
| 2018 | -3 Million USD | 78.31% |
| 2017 | -13.84 Million USD | -0.6% |
| 2016 | -13.75 Million USD | -0.56% |
| 2015 | -13.68 Million USD | -8.16% |
| 2014 | -12.65 Million USD | -52.78% |
| 2013 | -8.28 Million USD | -2.58% |
| 2012 | -8.07 Million USD | 32.12% |
| 2011 | -11.89 Million USD | 35.75% |
| 2010 | -18.5 Million USD | 40.59% |
| 2009 | -31.15 Million USD | -20.11% |
| 2008 | -25.94 Million USD | -16.46% |
| 2007 | -22.27 Million USD | -24.32% |
| 2006 | -17.91 Million USD | -37.31% |
| 2005 | -13.04 Million USD | -24.5% |
| 2004 | -10.48 Million USD | -12.83% |
| 2003 | -9.28 Million USD | 24.52% |
| 2002 | -12.3 Million USD | -249.06% |
| 2001 | -3.52 Million USD | 67.68% |
| 2000 | -10.9 Million USD | 7.19% |
| 1999 | -11.75 Million USD | 12.29% |
| 1998 | -13.4 Million USD | -30.1% |
| 1997 | -10.3 Million USD | -58.46% |
| 1996 | -6.5 Million USD | -62.5% |
| 1995 | -4 Million USD | -42.86% |
| 1994 | -2.8 Million USD | -40.0% |
| 1993 | -2 Million USD | -33.33% |
| 1992 | -1.5 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -167.22 Thousand USD | -47.38% |
| 2024 Q2 | -96.58 Thousand USD | 42.24% |
| 2023 Q4 | -113.46 Thousand USD | -883.67% |
| 2023 FY | -564.87 Thousand USD | 94.19% |
| 2023 Q3 | 14.47 Thousand USD | 100.23% |
| 2023 Q2 | -6.32 Million USD | -2293.61% |
| 2023 Q1 | -264.11 Thousand USD | 94.16% |
| 2022 Q3 | -595.43 Thousand USD | -132.31% |
| 2022 Q4 | -4.52 Million USD | -660.06% |
| 2022 Q1 | -4.34 Million USD | -186.78% |
| 2022 Q2 | -256.31 Thousand USD | 94.1% |
| 2022 FY | -9.72 Million USD | -6.53% |
| 2021 Q4 | -1.51 Million USD | 16.26% |
| 2021 Q2 | -3.76 Million USD | -84.71% |
| 2021 FY | -9.12 Million USD | -20.32% |
| 2021 Q3 | -1.8 Million USD | 51.94% |
| 2021 Q1 | -2.03 Million USD | 38.84% |
| 2020 Q3 | -1.61 Million USD | -11778.27% |
| 2020 FY | -7.58 Million USD | -75.94% |
| 2020 Q1 | -2.64 Million USD | -113.07% |
| 2020 Q2 | 13.84 Thousand USD | 100.52% |
| 2020 Q4 | -3.33 Million USD | -106.15% |
| 2019 Q2 | -1.16 Million USD | -83.12% |
| 2019 Q1 | -634 Thousand USD | -0.79% |
| 2019 FY | -4.31 Million USD | -43.6% |
| 2019 Q4 | -1.24 Million USD | -33.56% |
| 2019 Q3 | -930.71 Thousand USD | 19.84% |
| 2018 Q4 | -629 Thousand USD | 7.5% |
| 2018 Q2 | -898 Thousand USD | -12.96% |
| 2018 FY | -3 Million USD | 78.31% |
| 2018 Q1 | -795 Thousand USD | 67.36% |
| 2018 Q3 | -680 Thousand USD | 24.28% |
| 2017 Q1 | -3.97 Million USD | -14.24% |
| 2017 FY | -13.84 Million USD | -0.6% |
| 2017 Q4 | -2.43 Million USD | 31.19% |
| 2017 Q3 | -3.54 Million USD | 9.14% |
| 2017 Q2 | -3.89 Million USD | 1.86% |
| 2016 Q3 | -3.26 Million USD | 11.12% |
| 2016 Q4 | -3.47 Million USD | -6.53% |
| 2016 FY | -13.75 Million USD | -0.56% |
| 2016 Q1 | -3.35 Million USD | 15.74% |
| 2016 Q2 | -3.67 Million USD | -9.49% |
| 2015 Q1 | -2.77 Million USD | -4.99% |
| 2015 Q4 | -3.97 Million USD | -10.53% |
| 2015 FY | -13.68 Million USD | -8.16% |
| 2015 Q2 | -3.32 Million USD | -19.84% |
| 2015 Q3 | -3.59 Million USD | -8.14% |
| 2014 Q3 | -3.45 Million USD | 12.0% |
| 2014 Q1 | -2.62 Million USD | -25.32% |
| 2014 FY | -12.65 Million USD | -52.78% |
| 2014 Q2 | -3.92 Million USD | -49.32% |
| 2014 Q4 | -2.64 Million USD | 23.4% |
| 2013 Q3 | -2.64 Million USD | -59.94% |
| 2013 Q1 | -1.88 Million USD | -12.57% |
| 2013 Q4 | -2.09 Million USD | 20.78% |
| 2013 Q2 | -1.65 Million USD | 12.01% |
| 2013 FY | -8.28 Million USD | -2.58% |
| 2012 FY | -8.07 Million USD | 32.12% |
| 2012 Q1 | -1.88 Million USD | 20.5% |
| 2012 Q2 | -2.27 Million USD | -20.8% |
| 2012 Q3 | -2.23 Million USD | 1.67% |
| 2012 Q4 | -1.67 Million USD | 25.37% |
| 2011 Q1 | -3.06 Million USD | -76.02% |
| 2011 FY | -11.89 Million USD | 35.75% |
| 2011 Q4 | -2.37 Million USD | 33.27% |
| 2011 Q3 | -3.55 Million USD | -22.52% |
| 2011 Q2 | -2.9 Million USD | 5.48% |
| 2010 FY | -18.5 Million USD | 40.59% |
| 2010 Q2 | -5.02 Million USD | 21.44% |
| 2010 Q1 | -6.39 Million USD | 25.67% |
| 2010 Q3 | -3.63 Million USD | 27.68% |
| 2010 Q4 | -1.74 Million USD | 52.05% |
| 2009 Q3 | -7.74 Million USD | 5.32% |
| 2009 Q2 | -8.17 Million USD | -23.25% |
| 2009 FY | -31.15 Million USD | -20.11% |
| 2009 Q1 | -6.63 Million USD | -14.76% |
| 2009 Q4 | -8.6 Million USD | -11.21% |
| 2008 Q3 | -7.22 Million USD | -0.36% |
| 2008 Q1 | -5.73 Million USD | 6.81% |
| 2008 FY | -25.94 Million USD | -16.46% |
| 2008 Q4 | -5.78 Million USD | 20.0% |
| 2008 Q2 | -7.19 Million USD | -25.48% |
| 2007 Q4 | -6.15 Million USD | -7.45% |
| 2007 Q3 | -5.72 Million USD | 2.49% |
| 2007 FY | -22.27 Million USD | -24.32% |
| 2007 Q1 | -4.51 Million USD | -12.88% |
| 2007 Q2 | -5.87 Million USD | -30.18% |
| 2006 FY | -17.91 Million USD | -37.31% |
| 2006 Q4 | -3.99 Million USD | 8.39% |
| 2006 Q3 | -4.36 Million USD | 22.24% |
| 2006 Q2 | -5.61 Million USD | -42.36% |
| 2006 Q1 | -3.94 Million USD | -6.45% |
| 2005 Q1 | -2.21 Million USD | 3.15% |
| 2005 Q3 | -3.76 Million USD | -11.85% |
| 2005 Q4 | -3.7 Million USD | 1.65% |
| 2005 FY | -13.04 Million USD | -24.5% |
| 2005 Q2 | -3.36 Million USD | -52.03% |
| 2004 Q1 | -2.2 Million USD | 10.8% |
| 2004 FY | -10.48 Million USD | -12.83% |
| 2004 Q4 | -2.28 Million USD | 24.95% |
| 2004 Q3 | -3.04 Million USD | -3.54% |
| 2004 Q2 | -2.94 Million USD | -33.42% |
| 2003 Q1 | -1.46 Million USD | 39.35% |
| 2003 Q3 | -3.42 Million USD | -82.62% |
| 2003 Q2 | -1.87 Million USD | -27.79% |
| 2003 FY | -9.28 Million USD | 24.52% |
| 2003 Q4 | -2.47 Million USD | 27.85% |
| 2002 Q3 | -1.67 Million USD | 38.84% |
| 2002 Q1 | -5.48 Million USD | -244.63% |
| 2002 FY | -12.3 Million USD | -249.06% |
| 2002 Q4 | -2.42 Million USD | -44.85% |
| 2002 Q2 | -2.73 Million USD | 50.15% |
| 2001 Q4 | 3.78 Million USD | 287.66% |
| 2001 Q1 | -2.37 Million USD | 5.08% |
| 2001 Q3 | -2.01 Million USD | 38.22% |
| 2001 Q2 | -3.26 Million USD | -37.37% |
| 2001 FY | -3.52 Million USD | 67.68% |
| 2000 Q4 | -2.5 Million USD | 20.81% |
| 2000 Q2 | -1.99 Million USD | 38.59% |
| 2000 FY | -10.9 Million USD | 7.19% |
| 2000 Q1 | -3.24 Million USD | 0.28% |
| 2000 Q3 | -3.16 Million USD | -58.89% |
| 1999 Q3 | -3.5 Million USD | -29.63% |
| 1999 Q2 | -2.7 Million USD | -22.73% |
| 1999 Q1 | -2.2 Million USD | 43.59% |
| 1999 FY | -11.75 Million USD | 12.29% |
| 1999 Q4 | -3.25 Million USD | 7.06% |
| 1998 Q3 | -3.8 Million USD | -18.75% |
| 1998 Q4 | -3.9 Million USD | -2.63% |
| 1998 Q1 | -2.4 Million USD | 22.58% |
| 1998 Q2 | -3.2 Million USD | -33.33% |
| 1998 FY | -13.4 Million USD | -30.1% |
| 1997 Q2 | -2.9 Million USD | -38.1% |
| 1997 FY | -10.3 Million USD | -58.46% |
| 1997 Q4 | -3.1 Million USD | -47.62% |
| 1997 Q3 | -2.1 Million USD | 27.59% |
| 1997 Q1 | -2.1 Million USD | -23.53% |
| 1996 Q1 | -1.5 Million USD | 63.41% |
| 1996 Q2 | -1.9 Million USD | -26.67% |
| 1996 Q3 | -1.2 Million USD | 36.84% |
| 1996 Q4 | -1.7 Million USD | -41.67% |
| 1996 FY | -6.5 Million USD | -62.5% |
| 1995 Q2 | -700 Thousand USD | 30.0% |
| 1995 Q4 | -4.1 Million USD | -4200.0% |
| 1995 Q3 | 100 Thousand USD | 114.29% |
| 1995 FY | -4 Million USD | -42.86% |
| 1995 Q1 | -1 Million USD | 65.52% |
| 1994 Q3 | 100 Thousand USD | 120.0% |
| 1994 Q2 | -500 Thousand USD | -600.0% |
| 1994 Q1 | 100 Thousand USD | 116.67% |
| 1994 FY | -2.8 Million USD | -40.0% |
| 1994 Q4 | -2.9 Million USD | -3000.0% |
| 1993 Q1 | 100 Thousand USD | 106.25% |
| 1993 Q3 | -200 Thousand USD | -300.0% |
| 1993 Q4 | -600 Thousand USD | -200.0% |
| 1993 FY | -2 Million USD | -33.33% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| 1992 Q2 | 100 Thousand USD | 0.0% |
| 1992 Q3 | 100 Thousand USD | 0.0% |
| 1992 Q4 | -1.6 Million USD | -1700.0% |
| 1992 Q1 | 100 Thousand USD | 0.0% |
| 1992 FY | -1.5 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -397.818% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -31.788% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 62.75% |
| Nascent Biotech, Inc. | -2.22 Million USD | -198.133% |
| Rebus Holdings, Inc. | -664 Thousand USD | -901.207% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 108.122% |
| Qrons Inc. | -643.67 Thousand USD | -932.818% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1606.501% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 88.023% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1500.084% |
| Skye Bioscience, Inc. | -13.67 Million USD | 51.374% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 90.739% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 235.265% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -2440.067% |
| SQZ Biotechnologies Company | -75.82 Million USD | 91.232% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -133.222% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -332.8% |
| Mesoblast Limited | -84.14 Million USD | 92.1% |
| Marizyme, Inc. | -34.08 Million USD | 80.497% |
| Genus plc | 6.4 Million USD | 203.875% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 168.238% |
| Pharming Group N.V. | -4.87 Million USD | -36.243% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -234.663% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -613.781% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 20.383% |
| ContraFect Corporation | -56.88 Million USD | 88.314% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -45.959% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -374.184% |
| IMV Inc. | -38.67 Million USD | 82.809% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -141.672% |
| MultiCell Technologies, Inc. | -722.81 USD | -919645.853% |
| ONE Bio Corp. | 13.68 Million USD | 148.591% |
| Accustem Sciences Inc. | -3.74 Million USD | -77.45% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 88.73% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -1276.224% |
| Q BioMed Inc. | -3.44 Million USD | -92.941% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 287.797% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -153.015% |
| Biomind Labs Inc. | -1 Million USD | -558.478% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 87.907% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -129.143% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -256.582% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -22095.563% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 58.109% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -243.992% |
| GB Sciences, Inc. | -1.42 Million USD | -368.002% |
| Alpha Cognition Inc. | -9.7 Million USD | 31.503% |
| HST Global, Inc. | -140.9 Thousand USD | -4618.016% |
| CSL Limited | 3.7 Billion USD | 100.18% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -490.984% |
| Halberd Corporation | -75.05 Thousand USD | -8758.115% |
| Enzolytics Inc. | -2.14 Million USD | -209.383% |
| Agentix Corp. | -1.37 Million USD | -384.635% |
| Resverlogix Corp. | -12.74 Million USD | 47.855% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -109.831% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 98.436% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -536.783% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -127.715% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -320.932% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -95.244% |
| AVAX Technologies, Inc. | 6.69 Million USD | 199.33% |
| Zenith Capital Corp. | -8.94 Million USD | 25.662% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.401% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -38060.926% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -170.76% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -3776.178% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -231.612% |
| Kadimastem Ltd | -3.04 Million USD | -118.667% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -575.575% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -429.301% |
| BioStem Technologies, Inc. | -7.77 Million USD | 14.539% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -3563.121% |
| LadRx Corporation | -3.82 Million USD | -73.867% |
| Cell Source, Inc. | -4.32 Million USD | -53.699% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -867.758% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -867.758% |
| NovAccess Global Inc. | -2.46 Million USD | -169.504% |
| Affymax, Inc. | -15.04 Million USD | 55.815% |
| Itoco Inc. | -919.14 Thousand USD | -623.286% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -56.851% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -494.103% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1098.813% |
| CytoDyn Inc. | -18.05 Million USD | 63.185% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -26312.455% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -2920.754% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1077.217% |
| SYBLEU INC | -149.18 Thousand USD | -4356.371% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -266.016% |
| International Stem Cell Corporation | -663 Thousand USD | -902.717% |
| Bioxytran, Inc. | -3.82 Million USD | -74.025% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -12529.208% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -32584.44% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 81.669% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -310.879% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -803.465% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -113.694% |
| Neutra Corp. | -229.48 Thousand USD | -2796.915% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 62.096% |
| PureTech Health plc | -146.19 Million USD | 95.453% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 69.066% |
| IXICO plc | -1.43 Million USD | -362.632% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 29.955% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 94.542% |
| CSL Limited | 3.81 Billion USD | 100.174% |
| Cellectis S.A. | -108.85 Million USD | 93.893% |